Medication for Borderline Personality Disorder: Evidence and Limits
Author: Ukrainian Psychological Hub · Published: October 12, 2026 · Editorial Policy
Medication for borderline personality disorder (BPD) is sometimes prescribed to address a clearly identified symptom or a separate, co-occurring condition. No medication has established effectiveness as a comprehensive treatment for the disorder itself. Structured psychotherapy remains the principal evidence-based treatment. The American Psychiatric Association (APA) practice guideline, published in 2024, suggests that psychotropic medication used for BPD be time-limited, directed at a measurable target symptom, and added to psychotherapy rather than used as its replacement.
The practical question is therefore more precise than “Which pill treats BPD?” A patient and prescriber need to identify the problem requiring treatment, determine whether it reflects BPD, another condition, a medication effect, a physical illness, or a combination of factors, and weigh a realistic expected benefit against adverse effects and the risks of prolonged prescribing. A 2022 Cochrane systematic review found little reliable evidence that pharmacological treatments improve overall BPD severity. A newer 2026 network meta-analysis reported promising short-term effects for certain drugs on selected symptoms, especially anger and hostility, while emphasizing individualized indications and study limitations.
This guide explains what antidepressants, antipsychotics, anticonvulsants or mood stabilizers, and sedatives can and cannot do; why different guidelines sometimes sound different; how a safe medication decision is made; and which questions patients can take to a clinical appointment. It describes research findings rather than providing a drug selection or dosing plan for an individual reader.
The central answer: can medication treat BPD?
BPD is a clinical diagnosis involving enduring difficulties in such areas as emotion regulation, self-image, interpersonal relationships, and sometimes behavioral control. Its presentation varies substantially among individuals. An intense emotional episode, unstable relationship, angry reaction, or a screening questionnaire score alone does not establish BPD. Diagnosis requires a qualified clinician to assess the pattern over time, its context, functional impact, and alternative explanations. The National Institute of Mental Health (NIMH) describes psychotherapy as the primary treatment and medications as possible additions for selected symptoms or co-occurring disorders.
In the United States, medicines prescribed for BPD symptoms are generally used off-label: no drug has an FDA-approved indication specifically for treating BPD as a disorder. Off-label prescribing can be a legitimate clinical choice, but it requires a sound rationale and appropriate informed consent. A drug approved for major depressive disorder, bipolar disorder, schizophrenia, or epilepsy does not thereby become an established treatment for BPD. Cochrane’s review of randomized trials explicitly identifies this mismatch between frequent prescribing and uncertain disorder-specific benefit.
The distinction between core personality difficulties and a target symptom matters. A drug might be considered for a severe, persistent co-occurring major depressive episode, for example, while psychotherapy addresses enduring interpersonal patterns and emotion regulation. A clinician might also contemplate a brief, carefully monitored medication trial for a prominent symptom, although the evidence for this approach varies by medication and outcome. The improvement of a symptom during treatment is meaningful, but it does not by itself prove that the drug changed the underlying personality disorder.
What the major clinical guidelines actually recommend
The APA guideline recommends a comprehensive, person-centered assessment and a structured psychotherapy with evidence for BPD’s core features. Before a new medicine is introduced, the clinician should review co-occurring diagnoses, previous psychotherapy and other interventions, prior medication trials, and the complete current medication list. The guideline then suggests a limited-duration adjunctive medication only for a specific, measurable target. At least every six months, medications should be reviewed and reconciled to identify lack of benefit, adverse effects, unnecessary overlap, and options for tapering or discontinuation.
The APA's formulation is deliberately conditional. Its medication recommendation is graded as a suggestion supported by low-certainty evidence, while the recommendation to provide structured psychotherapy is stronger. The operational implication is to define success in observable, patient-relevant terms. “Help with my BPD” is too vague to judge. A more useful target may be the frequency or severity of a specific disruptive symptom, measured alongside quality of life, ability to work or study, relationships, and medication harms. APA’s full implementation discussion emphasizes tailoring and monitoring.
The United Kingdom’s NICE guideline CG78 takes a more restrictive position: drugs should not be prescribed specifically for BPD or its individual characteristic behaviors or symptoms, and antipsychotics should not be used for medium- or long-term BPD treatment. NICE allows treatment of co-occurring conditions on their own clinical merits and cautiously discusses very short-term sedative treatment in crisis situations under specified safeguards. That crisis provision is tied to its own clinical context and is not a general recommendation to seek sedatives.
These statements share an important foundation. Both guidelines place ongoing psychosocial care at the center, recognize the risks of routine or prolonged psychotropic prescribing, and distinguish BPD from treatable co-occurring conditions. Their difference concerns how far clinicians should go in using medication for selected BPD symptoms when evidence is sparse. A clinician should explain which guideline, evidence, setting, and individual circumstances inform a proposed prescription rather than presenting professional disagreement as settled fact.
What clinical trials and systematic reviews show
The 2022 Cochrane review evaluated 46 randomized studies involving 2,769 participants and 27 different medicines. Most trials were relatively small or short, and many had methodological limitations. For core outcomes such as overall BPD severity, self-harm, suicide-related outcomes, and psychosocial functioning, the pooled evidence generally suggested little or no demonstrated benefit, with very low certainty for much of the evidence. The review also had limited information about serious adverse events and long-term outcomes. The correct inference is that reliable evidence for pharmacological treatment of BPD pathology remains insufficient.
A separate 2021 systematic review and meta-analysis examined 21 randomized trials with 1,768 participants. It likewise concluded that antidepressants, second-generation antipsychotics, and anticonvulsants did not consistently reduce overall BPD severity. Small signals for anger, aggression, or affective lability were largely dependent on individual trials. Results for general psychiatric symptoms were sometimes better than results for the core disorder, a reminder that investigators measure different outcomes and that a positive score on one scale is not equivalent to broad functional recovery.
The 2026 network meta-analysis by Gerolymos and colleagues analyzed 35 randomized trials and 2,551 participants. It identified relatively favorable short-term signals for topiramate, lamotrigine, and aripiprazole on hostility, anger, or aggression in specific studied comparisons; carbamazepine and asenapine had weaker signals for impulsivity or emotional dysregulation. Risk of bias varied, evidence certainty differed by medication and outcome, and many comparisons remained indirect. The researchers concluded that any prescription should be restricted to individualized clinical indications. These findings do not demonstrate that any of those medications should routinely be prescribed to everyone diagnosed with BPD.
The review dates and samples matter. The 2026 analysis is newer as a publication, but its trial search covered a period ending in February 2024. Its results reflect selective symptom endpoints and different analytic assumptions rather than a new long-term cure. A network ranking may favor a drug in a particular outcome while providing little information about the person’s daily functioning, sustained benefit, drug interactions, pregnancy risks, or outcomes in people with multiple co-occurring conditions. Stronger conclusions will require larger, independent, longer-duration trials with broadly representative participants.
An especially useful case is lamotrigine. Earlier small trials and the 2026 network analysis suggested improvements on some anger-related outcomes. However, the much larger LABILE randomized trial found no clinically meaningful advantage for lamotrigine over placebo on overall BPD symptoms and related outcomes over a year. The studies need not be treated as mutually exclusive: a short-term signal in a selected symptom is different from evidence of general effectiveness across a year. It would be a mistake to use a favorable network ranking to erase the negative larger trial or to treat the negative trial as proof that no individual could ever respond.
Antidepressants: SSRIs, SNRIs, and other medications
Antidepressants are commonly encountered in BPD care because major depressive disorder, anxiety disorders, trauma-related conditions, and obsessive-compulsive symptoms can coexist with BPD. Selective serotonin reuptake inhibitors (SSRIs), such as sertraline or fluoxetine, and other antidepressants may be indicated for a properly assessed co-occurring disorder according to the evidence and guidance for that disorder. This is an indication for the separate disorder, not proof that the antidepressant directly treats BPD’s enduring problems with identity, interpersonal functioning, or emotion regulation.
The distinction also applies to depressive feelings in BPD. Emotional pain, emptiness, rejection sensitivity, and rapid changes in distress can occur as part of BPD, while a major depressive episode has its own course and diagnostic requirements. Both may occur together. An assessment of symptom duration, sleep, appetite, enjoyment, psychomotor changes, suicidal thinking, and longitudinal course informs clinical decisions. The Cochrane review and 2021 meta-analysis do not support antidepressants as consistently effective treatments for overall BPD severity.
Antidepressants can have adverse effects, including gastrointestinal symptoms, changes in sleep, sexual side effects, and, in some circumstances, agitation or mood activation. Certain antidepressants also have clinically important withdrawal effects or interactions. If bipolar disorder is suspected, a prescriber must assess the history of mania and hypomania before choosing an antidepressant. The decision should include a plan to evaluate symptom-specific benefit and a safe discontinuation strategy if treatment is unsuccessful. Stopping abruptly or changing doses independently can create avoidable problems.
Antipsychotics: potential short-term symptom effects and important harms
Second-generation antipsychotics, sometimes called atypical antipsychotics, have been studied for severe anger, marked agitation, transient suspiciousness, cognitive-perceptual symptoms, and other selected complaints in people diagnosed with BPD. Antipsychotic is a medication class, not an assertion that every person taking one has a psychotic disorder. Prescribers may use some of these agents across a range of diagnoses. In BPD, however, trial findings do not justify routine long-term antipsychotic use as a general solution. NICE CG78 specifically advises against medium- and long-term antipsychotic treatment for BPD.
A randomized study of extended-release quetiapine involving 95 participants found an advantage for one tested dose on a BPD symptom scale over the study period, with sedation and greater adverse-event burden in the higher-dose group. That is a short-term trial of a particular formulation and sample, not definitive evidence of durable functional recovery. Some studies of olanzapine or aripiprazole have also reported symptom-specific effects, while the 2022 Cochrane synthesis found uncertainty and incomplete safety information. The 2026 network meta-analysis particularly reported an anger-related signal for aripiprazole.
Potential adverse effects of antipsychotics include weight gain, changes in glucose and lipids, sedation, movement-related symptoms, akathisia, and, with some agents, cardiac or hormonal effects. The specific risk profile differs substantially from one drug to another and from one patient to another. APA implementation guidance discusses metabolic monitoring, movement-related adverse effects, and the need to weigh potential benefit against harm. Baseline physical health and ongoing monitoring are part of prescribing, not optional afterthoughts.
Severe or persistent psychotic symptoms require an independent psychiatric assessment. Brief stress-related suspiciousness or dissociation can occur in BPD, but these experiences are not interchangeable with a primary psychotic disorder, an episode of bipolar mania, substance-related symptoms, or a medical cause. The presence of one symptom does not establish which medication class, if any, is indicated.
Mood stabilizers and anticonvulsants: why the evidence is mixed
The phrase mood stabilizer can mislead readers because it groups medicines with different mechanisms, approved uses, and safety requirements. Some anticonvulsants are used to treat epilepsy, others are also used in bipolar disorder, and their use for BPD-related emotional volatility is often off-label. Medication that prevents manic episodes in bipolar disorder cannot be presumed to correct the shorter, often context-sensitive emotional shifts observed in BPD. Clinical evaluation has to establish what kind of mood problem is actually present.
Lamotrigine illustrates the uncertainty particularly clearly: the large LABILE trial did not find overall benefit for BPD at one year, although smaller and shorter studies have produced selected symptom findings summarized in the 2026 network meta-analysis. Lamotrigine also carries a serious skin-reaction risk and requires careful clinician-supervised initiation and adjustment. A network-meta-analysis signal for hostility is therefore an insufficient reason to offer it routinely as a BPD medication.
Topiramate has shown signals for anger or aggression in selected short trials, but it can cause cognitive slowing, attention and memory problems, sensory symptoms, and other adverse effects. Valproate or divalproex, carbamazepine, and related medications have variable and often limited BPD-specific research. Depending on the drug, monitoring may involve laboratory tests, interactions, and special consideration of pregnancy or reproductive plans. APA implementation guidance highlights important drug-specific risks, including reproductive risks associated with divalproex and cognitive effects associated with topiramate. None of these medicines should be chosen from an internet ranking without individualized medical evaluation.
If a person has a separate diagnosis, such as bipolar I disorder or epilepsy, medication decisions may be strongly supported for that condition even when BPD-specific evidence is weak. Treating a verified co-occurring disorder and treating BPD are different clinical actions, and the reason for every medicine on the chart should remain transparent.
Benzodiazepines, sleeping pills, and medication during crises
Benzodiazepines and related sedating medicines can rapidly change anxiety or arousal, which may make them appealing during intense distress. Yet rapid relief is a different outcome from lasting improvement in BPD. Sedation can impair judgment or coordination, and some medications in this area carry dependence, withdrawal, interaction, and overdose risks, especially when combined with alcohol, opioids, or other sedatives. Decisions about acute prescribing require attention to safety, substance use, access to medication, and the person’s individual clinical history.
A medication sometimes used briefly in a crisis does not become a standing treatment for emotion regulation or relationship distress. NICE guidance describes tightly limited crisis sedative use with informed consent, low-risk prescribing, and a short specified duration; it should not be read as an endorsement of unsupervised use. The APA guideline instead frames any BPD-targeted psychotropic treatment as time-limited and measurable, within an ongoing psychotherapy-centered plan.
For persistent sleep difficulties, the clinical task includes asking whether insomnia reflects anxiety, depression, trauma-related nightmares, disrupted routines, medication side effects, substance use, sleep apnea, or another condition. Sleep medications can be considered within that broader assessment. Giving several sedatives because sleep remains poor without investigating its cause can obscure the problem and compound risks.
Does medication reduce self-harm or suicide risk?
No medicine has established efficacy as a specific treatment for suicidal or self-injurious behavior attributable to BPD. The Cochrane review found uncertain evidence on these critical outcomes, in part because trials were short, samples were restricted, and serious adverse events were poorly captured. Medication response on an anger or general-symptom scale cannot be assumed to lower suicide attempts, emergency admissions, or mortality.
Risk assessment is individual and dynamic. Not everyone diagnosed with BPD self-harms or experiences suicidal crises, and people who do require care based on their current circumstances. A useful clinical plan considers recent behavior, changes in intent, access to potentially lethal means, substance use, social supports, stressors, and capacity to participate in treatment. The APA assessment recommendations emphasize evaluation of suicide, self-injury, and aggression risk within comprehensive psychiatric care. Appropriate structured psychotherapy, collaborative crisis planning, and access to emergency services are essential parts of safety-oriented treatment.
If a person has taken an overdose, is at immediate risk of acting on suicidal thoughts, or cannot remain safe, they need urgent local emergency care. In the United States, call or text 988 for the Suicide & Crisis Lifeline and call 911 for an immediate life-threatening emergency. In other countries, use the relevant local emergency or crisis service. These interventions address immediate safety; a general article cannot evaluate an individual emergency.
Co-occurring conditions: when medication has a clearer indication
The strongest medication rationale in many BPD treatment plans is a separately established co-occurring diagnosis. Major depressive disorder, bipolar disorder, ADHD, PTSD, anxiety disorders, substance use disorders, eating disorders, and physical health conditions can coexist with BPD. Their treatments should be selected according to the diagnostic evidence and risk profile of each condition. The NIMH clinical overview documents the overlap and stresses thorough professional assessment, while the APA guideline requires reviewing co-occurring disorders before new prescriptions.
Consider two superficially similar situations. In one, mood changes occur within minutes or hours and are closely associated with interpersonal events. In another, sustained periods of elevated or irritable mood occur with changes in energy, sleep need, and behavior meeting criteria for mania or hypomania. Both require thoughtful assessment, but they raise different medication questions. Readers can explore the already published English Hub comparison, Bipolar Disorder vs Borderline Personality Disorder, for the diagnostic distinction. A mood stabilizer appropriate for bipolar disorder should not be justified solely by the description “BPD mood swings.”
The same rule applies to attention problems, panic, dissociation, and trauma-related symptoms. Effective treatment may require psychotherapy, medication targeted at a verified co-occurring disorder, coordinated physical health care, or several approaches. Prescribing should avoid relabeling every difficult experience as a separate illness simply to assign a medication.
How clinicians decide whether a medication trial is justified
A sound decision begins with the patient’s goals and a careful longitudinal assessment. The clinician asks what has changed, how severe and frequent the target symptom is, what triggers or maintains it, what interventions have already helped, and how the symptom affects functioning. They assess diagnoses and differential diagnoses, current safety concerns, physical health, potential pregnancy, substance use, medication allergies, and the full medication list, including prescriptions from other clinicians and over-the-counter products. APA statement 6 explicitly calls for review of existing treatments and prior trials before starting a new medicine.
The next step is a shared explanation of the proposed indication. The prescriber should state whether the medicine is treating a separate condition or is an off-label, symptom-targeted trial related to BPD; which outcome is expected to change; how the outcome will be measured; what evidence supports the expectation; and which harms must be monitored. A time frame for reevaluation and the circumstances for stopping should be decided at the outset. An unsuccessful trial should produce a change in the plan, not indefinite accumulation of prescriptions.
For example, a patient may describe frequent, severe episodes of agitation that disrupt work and sleep. The care team can first examine medication activation, alcohol or stimulant exposure, physical illness, the timing of conflicts, mood episodes, and available psychological tools. If a carefully chosen medicine is tried, the team can monitor the frequency, intensity, duration, and consequences of agitation alongside adverse effects. A decrease in distress without improvement in concentration, participation, or relationships may still require a different care strategy.
Individual preference is a legitimate part of the decision. Some people prefer to avoid medications because of past adverse effects; others value a cautious adjunctive trial for disabling symptoms. Good consent explains realistic evidence and choice without pressuring the patient toward a particular medication class.
Medication review, polypharmacy, and safe discontinuation
Polypharmacy means using several medicines at the same time, often from overlapping psychotropic classes. It can arise gradually: one drug is added for insomnia, another for anxiety, a third for mood fluctuation, while older prescriptions remain active. The benefits of each addition may become impossible to judge, and interaction or adverse-effect risks can grow. The APA guideline recommends medication reconciliation at least every six months; sooner review is appropriate when side effects, new symptoms, missed doses, changes in health, or new prescriptions occur.
A medication review asks whether the original diagnosis and target are still valid, whether an objective benefit occurred, how long the drug has been used, what monitoring is current, and whether a simpler regimen could work. It should also examine whether a new symptom may be a side effect: for example, restlessness from one drug can resemble worsening agitation, while sedation can resemble fatigue or depression. APA implementation guidance describes ongoing monitoring tailored to the specific medication.
Discontinuation must be planned with a clinician. Some antidepressants and sedatives can cause withdrawal symptoms after abrupt cessation; some anticonvulsants and antipsychotics require condition-specific tapering or monitoring. A safe plan considers why the medicine was prescribed, duration of use, dose, interactions, other diagnoses, and the possibility of symptom recurrence. A recommendation to avoid unnecessary medication is not an instruction to stop current treatment immediately.
Why psychotherapy remains the foundation of BPD care
Psychotherapy can address difficulties that medication trials have not reliably resolved: patterns of emotion regulation, the relationship between emotion and behavior, self-image, interpersonal trust, responses to perceived rejection, and the development of a workable sense of agency. The APA 2024 practice guideline recommends a structured psychotherapy with research support that targets BPD’s core features. The NIMH likewise places psychotherapy first and identifies dialectical behavior therapy (DBT) among the approaches specifically developed for BPD.
Different structured approaches can emphasize different mechanisms. DBT teaches emotion-regulation, distress-tolerance, mindfulness, and interpersonal-effectiveness skills within a treatment framework. Other approaches used in specialized settings include mentalization-based treatment, transference-focused psychotherapy, and schema therapy. Treatment selection depends on access, patient preference, presentation, and clinician training; comparisons do not support assuming that one approach will be uniquely best for every person.
Medication can sometimes make it easier to participate in therapy when a separately treatable condition is impairing sleep, concentration, or emotional stability. Even then, the clinical goal is broader than symptom suppression: sustained functioning, safer coping, more stable relationships, and a life guided by the patient’s own goals. Psychotherapy and medication clinicians should communicate when the patient agrees, so adverse effects, crisis planning, progress, and treatment changes are understood consistently.
What a realistic recovery outlook looks like
A diagnosis of BPD does not imply that a person will experience the same level of impairment throughout life. Clinical course and response to treatment vary. Improvement can involve less intense or less frequent symptoms, more effective coping, steadier self-understanding, improved work or school participation, and more satisfying relationships. Recovery goals should be defined with the person rather than reduced to one rating scale or the number of medications prescribed. The NIMH emphasizes that effective treatments can improve symptoms, functioning, and quality of life.
Drug trials rarely measure the full duration and breadth of recovery that matters to patients. Short-term improvement in hostility does not settle long-term functioning, and a lack of benefit from one drug does not mean that treatment as a whole has failed. An evidence-based care plan can continue to evolve as symptoms change, personal circumstances stabilize, and psychological skills develop.
Questions to ask before starting or changing a medication
A useful medication appointment is a collaborative clinical discussion. Ask the prescriber: What specific condition or symptom is this drug intended to treat? Is its use for BPD off-label? What is the quality of evidence for this particular target? What change should I realistically expect, and how will we measure it? How soon will we review the result? What adverse effects and interactions matter given my health history? What laboratory tests or other monitoring are needed? What are the considerations for pregnancy or breastfeeding, if relevant? How will this medicine fit with psychotherapy and the crisis plan? When would we consider tapering or stopping it?
Bring an up-to-date list of prescriptions, supplements, substances, previous medication trials, allergies, and important side effects. If different professionals prescribe medicines, ask who coordinates the overall list. Record the agreed goals in understandable language; this makes shared decision-making and future medication review much more concrete.
Common misunderstandings about BPD medication
“A strong medication means my BPD is severe.” Prescriptions reflect a clinician’s assessment of symptoms, co-occurring conditions, risks, local practice, and sometimes historical prescribing patterns. The number or type of medicines is not a diagnostic severity scale. Similarly, “I improved on an antidepressant, so I cannot have BPD” is a faulty conclusion: response to a treatment does not determine which disorders are present.
“If my mood changes quickly, I need a bipolar mood stabilizer.” The duration, context, and associated symptoms of mood changes matter. Bipolar disorder and BPD may coexist, but the diagnostic evaluation should establish each separately. “An antipsychotic means I have schizophrenia” is also incorrect: clinicians prescribe drugs from that class for multiple indications, and some BPD studies have examined selected symptoms.
“Medication does nothing for anybody with BPD” overshoots the science. Selective benefits for certain symptoms or well-diagnosed co-occurring conditions can be real. Equally, “a 2026 analysis ranked a drug highest, so it is the best BPD treatment” misreads small short-term comparisons as a general prescribing recommendation. Both assumptions skip individual risk–benefit assessment and the APA’s emphasis on measurable, time-limited adjunctive use.
Frequently asked questions about BPD medication
What is the best medication for borderline personality disorder?
There is no established best medication for BPD as a whole. Current guidelines prioritize structured psychotherapy and a careful assessment of specific needs. A prescriber may consider medicine for a separate diagnosed disorder or a narrowly defined symptom, but should explain the evidence and reasons for the choice. The Cochrane review found insufficient reliable evidence for a medication that consistently reduces overall BPD pathology.
Are any medications FDA-approved specifically for BPD?
No medication is currently approved in the United States specifically to treat borderline personality disorder. Drugs sometimes used in BPD care have approved indications for other conditions, and symptom-directed BPD prescribing is generally off-label. This differs from using an approved medication for a genuinely co-occurring condition. See the Cochrane evidence summary.
Can SSRIs treat BPD-related emotional instability?
SSRIs may be useful for a properly assessed co-occurring depression or anxiety disorder, but trials have not established consistent improvement of BPD’s core features. Emotional instability has multiple possible clinical explanations, so a prescriber should distinguish a major depressive episode or anxiety disorder from BPD-related emotional responses before making a medication decision. 2021 systematic review.
Is lamotrigine effective for borderline personality disorder?
The findings are mixed across different outcomes and study sizes. Small trials have produced some selected symptom signals, but the large LABILE randomized trial did not show meaningful overall BPD benefit at one year. A 2026 network meta-analysis reported short-term benefits on anger-related outcomes in some comparisons. These results do not support routine lamotrigine prescribing for BPD.
Can antipsychotics help with anger, agitation, or paranoia?
Some short-term trials indicate potential symptom-specific improvements, but the size and durability of the benefits are uncertain and adverse effects can be substantial. Treatment of severe or sustained psychosis also requires a distinct clinical evaluation. NICE guidance advises against medium- and long-term antipsychotic use for BPD itself.
Is BPD medication the same as medication for bipolar disorder?
No. BPD and bipolar disorder involve different clinical patterns, although both may occur in the same person. Mood stabilizers prescribed for verified bipolar illness may be appropriate for that illness even though the evidence for BPD-specific treatment remains limited. The relevant question is the established diagnosis and treatment target, not the informal phrase “mood swings.” See Bipolar Disorder vs Borderline Personality Disorder.
Can a doctor prescribe a medication only for a short period?
Yes, a time-limited trial can be considered in selected circumstances after an individualized assessment, discussion of evidence and side effects, and agreement on a measurable target. The APA guideline specifically suggests this adjunctive, time-limited approach, while NICE remains more restrictive about prescribing for BPD symptoms.
How often should BPD medications be reviewed?
The APA guideline recommends medication review and reconciliation at least every six months. Earlier review may be necessary after initiation, a dose change, a side effect, a crisis, or a new diagnosis. A review should ask whether each drug still has a valid indication and measurable benefit.
What if medication helps anxiety but relationships remain difficult?
This can happen because relief of one symptom and improvement in personality functioning are different outcomes. It may still be valuable to treat a disabling anxiety disorder while psychotherapy addresses interpersonal patterns, self-understanding, and emotion regulation. A combined plan should measure each outcome independently and adapt to the patient’s priorities.
Should I stop a medication if I read that it does not treat BPD?
Do not stop, reduce, or replace prescribed medication based solely on an article. The medicine may be addressing a separate condition, and abrupt changes can produce withdrawal effects or other risks. Request a medication review with the prescribing clinician, including the original indication, demonstrated benefit, harms, and a supervised taper if one is appropriate. NIMH guidance recommends discussing medication concerns with a health care provider before changing treatment.
Related Articles
Bipolar Disorder vs Borderline Personality Disorder: How Clinicians Distinguish Them — an important distinction when evaluating mood episodes and indications for mood-stabilizing medications.
DID vs Borderline Personality Disorder: Symptoms and Diagnostic Differences — diagnostic context for dissociation and identity-related symptoms that may otherwise be misinterpreted in medication decisions.
For the broader clinical guidance on medicines used across personality disorders, see Are Medications Used for Personality Disorders? Clinical Guidance.
References
American Psychiatric Association. (2024). The American Psychiatric Association practice guideline for the treatment of patients with borderline personality disorder. American Journal of Psychiatry, 181(11). DOI: 10.1176/appi.ajp.24181010.
American Psychiatric Association. (2024). Guideline statements and implementation. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Borderline Personality Disorder. DOI: 10.1176/appi.books.9780890428009.apapgpersondisorder03.
Black, D. W., Zanarini, M. C., Romine, A., Shaw, M., Allen, J., & Schulz, S. C. (2014). Comparison of low and moderate dosages of extended-release quetiapine in borderline personality disorder: A randomized, double-blind, placebo-controlled trial. American Journal of Psychiatry, 171(11), 1174–1182. DOI: 10.1176/appi.ajp.2014.13101348.
Crawford, M. J., et al. (2018). The clinical effectiveness and cost-effectiveness of lamotrigine in borderline personality disorder: A randomized placebo-controlled trial. American Journal of Psychiatry, 175(8), 756–764. DOI: 10.1176/appi.ajp.2018.17091006.
Gartlehner, G., et al. (2021). Pharmacological treatments for borderline personality disorder: A systematic review and meta-analysis. CNS Drugs. PubMed PMID: 34495494.
Gerolymos, C., Garosi, A., Boyer, L., Yon, D. K., Rahmati, M., Gavaudan, M., & Fond, G. (2026). Efficacy and safety of pharmacological treatments in borderline personality disorder: A systematic review and network meta-analysis. Molecular Psychiatry, 31, 3216–3228. DOI: 10.1038/s41380-026-03451-4.
National Institute for Health and Care Excellence. (2009; current online guidance). Borderline personality disorder: Recognition and management (CG78), recommendations. NICE.
National Institute of Mental Health. (2025 revision). Borderline personality disorder. U.S. National Institutes of Health.
Stoffers-Winterling, J. M., et al. (2022). Pharmacological interventions for people with borderline personality disorder. Cochrane Database of Systematic Reviews, 2022(11), CD012956. DOI: 10.1002/14651858.CD012956.pub2.